Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

British Journal of Haematology

Volumn 135, Issue 5, 2006, Pages 688-692

  Terpos, Evangelos ^a,b,d   Heath, Deborah J ^c   Rahemtulla, Amin ^b   Zervas, Kostas ^a   Chantry, Andrew ^c   Anagnostopoulos, Athanasios ^a   Pouli, Anastasia ^a   Katodritou, Eirini ^a   Verrou, Evgenia ^a   Vervessou, Elisavet Christine ^a   Dimopoulos, Meletios Athanassios ^a   Croucher, Peter I ^c  

^a Greek Myeloma Study Group   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Bone markers; Bortezomib; Dickkopf 1; Multiple myeloma; Receptor activator of nuclear factor kappa B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE REMODELING; CANCER RELAPSE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; BORONIC ACIDS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOCALCIN; OSTEOPROTEGERIN; PEPTIDES; PROTEASE INHIBITORS; PYRAZINES; RANK LIGAND; RECURRENCE; STATISTICS, NONPARAMETRIC;

EID: 33750566914     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06356.x     Document Type: Article

References (12)

1. Bataille, R., Delmas, P.D., Chappard, D. & Sany, J. (1990) Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer, 66, 167-172.
2. Gunn, W.G., Conley, A., Deininger, L., Olson, S.D., Prockop, D.J. & Gregory, C.A. (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells, 24, 986-991.
3. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N.C., Mitsiades, N. & Anderson, K.C. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 1530-1534.
4. Politou, M.C., Heath, D.J., Rahemtulla, A., Szydlo, R., Anagnostopoulos, A., Dimopoulos, M.A., Croucher, P.I. & Terpos, E. (2006) Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer, 119, 1728-1731.
5. Shimazaki, C., Uchida, R., Nakano, S., Namura, K., Fuchida, S.I., Okano, A., Okamoto, M. & Inaba, T. (2005) High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia, 19, 1102-1103.
6. Silvestris, F., Cafforio, P., Calvani, N. & Dammacco, F. (2004) Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology, 126, 475-486.
7. Terpos, E., Politou, M. & Rahemtulla, A. (2003a) New insights into the pathophysiology and management of bone disease in multiple myeloma. British Journal of Haematology, 123, 758-769.
8. Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M. & Rahemtulla, A. (2003b) Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102, 1064-1069.
9. Terpos, E., Politou, M., Szydlo, R., Nadal, E., Avery, S., Olavarria, E., Kanfer, E., Goldman, J.M., Apperley, J.F. & Rahemtulla, A. (2004) Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia, 18, 1420-1426.
10. Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C., Politou, M., Voskaridou, E., Rahemtulla, A., Dimopoulos, M.A. & Zervas, K. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 19, 1969-1976.
11. Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B. & Shaughnessy, Jr, J.D. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine, 349, 2483-2494.
12. Zangari, M., Esseltine, D., Lee, C.K., Barlogie, B., Elice, F., Burns, M.J., Kang, S.H., Yaccoby, S., Najarian, K., Richardson, P., Sonneveld, P. & Tricot, G. (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 131, 71-73.